Senazodan hydrochloride MCI 154 hydrochloride|cas:98326-33-1|西域试剂

Senazodan hydrochloride MCI 154 hydrochloride,99.74%

产品编号：Bellancom-101693A| CAS NO：98326-33-1| 分子式：C₁₅H₁₅ClN₄O| 分子量：302.76

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-101693A	￥3000.00	杭州北京（现货）
Bellancom-101693A	￥4800.00	杭州北京（现货）
Bellancom-101693A	￥9500.00	杭州北京（现货）
Bellancom-101693A	￥14500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Senazodan hydrochloride MCI 154 hydrochloride

产品介绍

Senazodan (MCI 154) (hydrochloride) 是一种 Ca²⁺ 感光剂，同时可抑制 PDE III 的活性。

生物活性

Senazodan (MCI 154) (hydrochloride), as a Ca²⁺ sensitiser, shows inhibition effect on PDE III.

体外研究

Senazodan (hydrochloride) seems to affect directly the actin-myosin crossbridge kinetics, and increases myosin ATPase activity. Senazodan (hydrochloride) produces a concentration-dependent increase in tension development. Senazodan (hydrochloride) enhances Ca²⁺ binding to myofilaments and to purified cardiac troponin C. Senazodan (hydrochloride) also enhances contractility in guinea-pig papillary muscles by inhibiting PDE III.Senazodan (0.1 nM~0.1 mM) (hydrochloride) shows that the contractile response of superior mesenteric arterie (SMA) to norepinephrine (NE) after hemorrhagic shock is significantly decreased as compared with the normal control group. Senazodan (0.01 mM) (hydrochloride) pretreatment prevents the effects of Ang II, and the concentration-response curve of Ca²⁺ is shifted to the right as compared with Ang II-alone group.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Senazodan (0.1~2.0 mg/kg; left femoral vein catheterization infusion) (hydrochloride) decreases the pressor effect of norepinephrine (NE).
Senazodan (0.1 mg/kg; i.v.) (hydrochloride) makes LVSP, IP, MC, and Lo all increased significantly, while heart rate is not obviously changed and left ventricular end-diastolic pressure (LVEDP) is reduced remarkably^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wistar rats (200~250 g)
Dosage:	0.1~2.0 mg/kg
Administration:	Left femoral vein catheterization infusion
Result:	Decreased the pressor effect of norepinephrine (NE).

Animal Model:	Rabbits^[4]
Dosage:	0.1 mg/kg
Administration:	I.v.
Result:	LVSP, IP, MC, and Lo all were increased significantly while heart rate was not obviously changed and left ventricular end-diastolic pressure (LVEDP) was reduced remarkably.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wistar rats (200~250 g)
Dosage:	0.1~2.0 mg/kg
Administration:	Left femoral vein catheterization infusion
Result:	Decreased the pressor effect of norepinephrine (NE).

Animal Model:	Rabbits^[4]
Dosage:	0.1 mg/kg
Administration:	I.v.
Result:	LVSP, IP, MC, and Lo all were increased significantly while heart rate was not obviously changed and left ventricular end-diastolic pressure (LVEDP) was reduced remarkably.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (165.15 mM; Need ultrasonic)

H₂O : 25 mg/mL (82.57 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.3029 mL	16.5147 mL	33.0295 mL
5 mM	0.6606 mL	3.3029 mL	6.6059 mL
10 mM	0.3303 mL	1.6515 mL	3.3029 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (8.26 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.26 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (8.26 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.26 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明